Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
Dianthus Therapeutics, Inc. (DNTH)
Company Research
Source: GlobeNewswire
NEW YORK and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company’s participation and corporate overview presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during November and December 2024: Guggenheim Healthcare Innovation Conference on November 11 at 1:30 p.m. ET in Boston, MAJefferies Global Healthcare Conference on November 19 at 9:00 a.m. GMT in London7th Annual Evercore HealthCONx Conference on December 4 at 10:50 a.m. ET in Coral Gables, FL Live webcasts of the Company’s presentations at these three conferences may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website. About Dianthus TherapeuticsDianthus Therapeutics is a clinical-stage biotechnology compa
Show less
Read more
Impact Snapshot
Event Time:
DNTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNTH alerts
High impacting Dianthus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DNTH
News
- Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.MarketBeat
- Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target raised by analysts at Oppenheimer Holdings Inc. from $48.00 to $52.00. They now have an "outperform" rating on the stock.MarketBeat
- Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target raised by analysts at Raymond James from $51.00 to $56.00. They now have an "outperform" rating on the stock.MarketBeat
- Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial ResultsGlobeNewswire
DNTH
Earnings
- 8/8/24 - Miss
DNTH
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/8/24 - Form SC
- DNTH's page on the SEC website